| Name | Title | Contact Details |
|---|
Arcutis was founded in 2016 to address significant unmet needs in medical dermatology. The company is a clinical-stage biopharmaceutical company focused on developing and commercializing best-in-class products. Our strategy is to exploit recent innovations in inflammation and immunology to bring the best molecules to bear against validated physiologic targets known to treat dermatological diseases and disorders. Our management team has extensive expertise in the development and commercialization of medical dermatology products, having held key leadership roles at a number of leading dermatology companies and, collectively, has successfully developed more than 50 FDA-approved products. We believe that by leveraging our team`s unique experience and demonstrated expertise to identify, develop and commercialize best-in-class molecules against validated targets, we will be able to develop differentiated products in less time, at lower cost, and at substantially lower risk than other approaches. Arcutis` combination of vision, unmet medical need, experienced management and strategic approach has attracted support from leading investors in the life sciences sector.
Avectas is a cell engineering technology business developing a unique delivery platform to enable the ex vivo manufacture of gene-modified cell therapy products, which will retain high in vivo functionality. Our vision is to position the non-viral SOLUPORE® cell engineering technology to be integrated into manufacturing processes for multiple autologous and allogeneic therapies and commercialised through development and license agreements.
Bellerophon Therapeutics is a clinical-stage biotherapeutics company focused on developing innovative products combining novel drugs and devices in the treatment of cardiopulmonary and cardiac diseases.
Kirin Pharma USA is a La Jolla, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
Owlstone Medical has developed a breathalyzer for disease. With a focus on non-invasive early detection and precision medicine for cancer, inflammatory disease and infectious disease, the company aims to save 100,000 lives and $1.5B in healthcare costs.